Wave Neuroscience

Open enrollment with a later-stage pipeline tilt

According to ClinicalTrials.gov-derived indexes, Wave Neuroscience sits in the top decile of US sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count).

11 total trials 1 currently recruiting 10 completed later-stage tilt top decile by trial count

Wave Neuroscience: 11 sponsored US clinical trials, 1 recruiting.

Wave Neuroscience sponsors 11 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 10 completed. 1 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Autistic Disorder, with 2 trials.

Top-decile sponsor footprint

Wave Neuroscience ranks in the top decile of sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

A 90/100

10 of 10 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

11 total, page 1 of 1

RECRUITING NA

EEG-based Personalized Transcranial Magnetic Stimulation (eTMS) to Treat Post-Traumatic Stress Disorder

NCT06892028
COMPLETED NA

EEG Personalized Transcranial Magnetic Stimulation (eTMS) for Post-Traumatic Stress Disorder

NCT06081309
COMPLETED NA

Clinical Trial to Evaluate the Safety and Efficacy of MeRT Treatment in Post-Traumatic Stress Disorder

NCT02990793
COMPLETED NA

Adaptive Design Study of NEST sTMS in Subjects With Major Depressive Disorder

NCT03288714
COMPLETED

A Longitudinal Study on the Safety and Efficacy for Subjects With ASD Who Received MeRT

NCT02746445
COMPLETED

A Chart Review to Evaluate the Safety and Efficacy of MeRT on Subjects With ASD

NCT02758496
COMPLETED NA

A Randomized, Double-blind, Sham-controlled Pilot Study to Evaluate the Treatment Efficacy of Magnetic EEG/ECG-Guided Resonance Therapy (MeRT) in College Students With ADHD

NCT03066505
COMPLETED NA

Trial to Evaluate Efficacy of Magnetic Resonant Therapy (MRT) in PTSD

NCT02268084
COMPLETED NA

A Trial To Evaluate The Efficacy of Magnetic Resonant Therapy in Autism

NCT01985308
COMPLETED Phase 3

Synchronized Transcranial Magnetic Stimulation (sTMS) in Major Depressive Disorder

NCT01370733
COMPLETED NA

Feasibility Study to Test Clinical Efficacy of Low Energy AC Magnetic Field to Treat Major Depression

NCT01683019

Phase Distribution

PhaseTrial count
Phase 3 1

Therapeutic Areas

Autistic Disorder 2
Postconcussive Symptoms 1
Stress Disorder, Post Traumatic 1
Post Traumatic Stress Disorder 1
Traumatic Brain Injury 1
Major Depressive Disorder 1

Where Wave Neuroscience enrollment is open (later-stage tilt)

1 recruiting of 11 indexed (9% open); 10 completed (91%).

Phase mix: 1 late (III/IV) vs 0 early (I/II) (later-stage heavy).

Top condition: Autistic Disorder (2 trials), 5 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Wave Neuroscience: open-pipeline peers nationwide

Peers matched on 11 registered trials and 9% open enrollment, not the therapeutic-area sidebar.

Wave Neuroscience sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 020406080 0%2%4%6%8%10% Total trials Recruiting share Wave NeuroscienceAderans Research InstituteAegerion PharmaceuticalsAllena PharmaceuticalsAOBiomeAlkermesDBV TechnologiesFlorida Gulf Coast UniversityGenfit
Wave Neuroscience sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Wave Neuroscience sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 11 trials (± recruiting share)

Sponsors near 9% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Wave Neuroscience page

11 registered trials is a research-attention snapshot, not an endorsement of Wave Neuroscience or any single study.

  • 1 of Wave Neuroscience's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Autistic Disorder is the condition Wave Neuroscience studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Autistic Disorder trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Wave Neuroscience pipeline card: 11 registered trials from official public datasets.Report a data error.